Skip to main content
HairCited

マイクロニードリング 男性型・女性型脱毛症(AGA)

A

合計8,451名の参加者を対象とした52件の研究(メタアナリシス5件、RCT 11件を含む)に基づく。52件中44件の研究で肯定的な効果が示されている。

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dmicroneedling\u0026condition\u003Dandrogenetic\u002Dalopecia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

結論

Microneedling has strong, well-established evidence for androgenetic alopecia, particularly when combined with topical minoxidil, and is one of the best-supported adjunct therapies for pattern hair loss.

  • 44 out of 52 studies show positive effects, supported by 5 meta-analyses and 11 RCTs
  • Most effective when combined with topical minoxidil, significantly boosting its effectiveness
  • Stimulates growth factors and wound-healing pathways that support hair follicle regeneration
  • Both professional and at-home microneedling approaches have demonstrated benefits

Key Study Findings

non-randomized controlled trial n=60 16 weeks Open-label
Clinical Efficacy and Mechanisms of Microneedling Alone or Combined With Drugs in the Treatment of …
Dose: Mild group: microneedling alone (8 weeks); Moderate group: microneedling + 5% minoxidil (12 weeks); vs: Placebo 効果: All groups showed significant decrease in HLSS and increase in hair density post-treatment (p<0.001) p<0.001
Controlled Clinical Trial n=8 12 weeks Single-blind
Dutasteride Infusion in Male Androgenetic Alopecia Using a Novel Drug Delivery Technique: MMP®.
Dose: 3 sessions of dutasteride microinfusion (monthly) vs: Saline solution placebo via MMP Outcome: Clinical assessment and patient self-assessment 効果: None None

対象集団: Adult males with androgenetic alopecia

Review
Microneedling Combined With Drugs and Stem Cells for Treating Androgenetic Alopecia.
Dose: None vs: None Outcome: None 効果: None None

対象集団: None

review
The role of microtrauma in hair regrowth and regeneration in non-scarring alopecia.
Dose: Various microtrauma procedures: microneedling, fractional/non-fractional lasers, contact immunothera vs: Placebo 効果: Positive outcomes reported for hair density and thickness with microneedling, lasers, LLLT, and PRP None
scoping_review n=16
A Scoping Review of Exosome Delivery Applications in Hair Loss.
Dose: variable; exosomes predominantly from mesenchymal stem cells (MSCs) vs: Placebo 効果: None None

Key Statistics

62

研究数

8574

参加者数

Positive

A

グレード

Referenced Papers

Aesthetic plastic surgery 2025 14 件の引用
Journal of cutaneous … 2025 2 件の引用
Dermatology (Basel, Switzerland) 2024 14 件の引用
Journal of cosmetic … 2024 11 件の引用
Journal of clinical … 2024 10 件の引用
Clinical, cosmetic and … 2023 58 件の引用
Skin appendage disorders 2023 4 件の引用
Faculty reviews 2022 44 件の引用
Dermatology and therapy 2022 43 件の引用
Journal of cosmetic … 2022 35 件の引用
Dermatologic surgery : … 2022 15 件の引用
Dermatologic surgery : … 2021 58 件の引用
Dermatologic therapy 2020 48 件の引用
Journal of plastic, … 2018 137 件の引用
Journal of the … 2018 114 件の引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

hairloss:
1.5 mm depth, weekly sessions

上限量: Not applicable

研究で検討された用量

用量 期間 効果 N
Mild group: microneedling alone (8 weeks); Moderate group: microneedling + 5% minoxidil (12 weeks); 16 weeks Positive 60
3 sessions of dutasteride microinfusion (monthly) 12 weeks Positive 8
None -- Mixed --
Various microtrauma procedures: microneedling, fractional/non-fractional lasers, contact immunothera -- Positive --
None -- Mixed --
variable; exosomes predominantly from mesenchymal stem cells (MSCs) -- Positive 16
None -- Positive 631
None -- Mixed --

推奨摂取タイミング: Weekly sessions; avoid minoxidil for 24 hours post-treatment

Safety & Side Effects

報告されている副作用

  • Scalp redness and inflammation (24-72 hours)
  • Mild bleeding at treatment site
  • Scalp tenderness and soreness
  • Rare: infection if proper sterilization not maintained

既知の相互作用

  • Topical minoxidil (enhanced absorption; wait 24 hours after microneedling to apply)
  • Blood thinners (may increase bleeding during procedure)
  • Topical retinoids (discontinue 3-5 days before treatment)

耐容上限摂取量: Not applicable

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does マイクロニードリング help with 男性型・女性型脱毛症(AGA)?
Based on 62 studies with 8,574 participants, there is strong evidence from multiple clinical trials that マイクロニードリング may support 男性型・女性型脱毛症(AGA) management. Our evidence grade is A (Strong Evidence).
How much マイクロニードリング should I take for 男性型・女性型脱毛症(AGA)?
Studies have used various dosages. A commonly studied range is 1.5 mm depth, weekly sessions. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of マイクロニードリング?
Reported side effects may include Scalp redness and inflammation (24-72 hours), Mild bleeding at treatment site, Scalp tenderness and soreness, Rare: infection if proper sterilization not maintained. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for マイクロニードリング and 男性型・女性型脱毛症(AGA)?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 62 peer-reviewed studies with 8,574 total participants. The overall direction of effect is positive.

Related Evidence

マイクロニードリング 他の症状・状態について

FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。